Documents GI ASCO single slide per page 1-17-15

New anti-angiogenic therapy in mCRC: FOLFIRI +/- Ramucirumab in 2nd line after FOLFOX + Bevacizumab (phase III: RAISE study) or single agent Famitinib in 3rd line (phase…

Documents Post G.I. ASCO Update: Colorectal Cancer

Chemotherapy of Colorectal Cancer Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D. Disclosure of Potential Conflicts of Interest Dr. Ronald Burkes Amgen Inc.,…